Urinary Bladder
C67WHO Vol. 8
Urinary Tract
★ 8.0Nature Reviews Clinical Oncology
2026-08-04
Benefit from perioperative enfortumab vedotin–pembrolizumab in cisplatin-eligible MIBC
In the randomized phase 3 KEYNOTE-B15/EV-304 trial (n=808), perioperative enfortumab vedotin plus pembrolizumab outperformed standard neoadjuvant cisplatin-gemcitabine in cisplatin-eligible muscle-invasive bladder cancer. At 2 years, event-free survival was 79.4% versus 66.2% (HR 0.53; 95% CI 0.41-0…
Read the full story →